CorMedix (CRMD) Tops Q4 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to CorMedix (CRMD) Tops Q4 EPS by 5c

CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 25, 2025 7:30 AM EDT

Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm

Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm

Conference Call Scheduled for Today at 8:30 a.m. Eastern Time

BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided an update on its business.

Recent Corporate... More